Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
about
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
P2860
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Is there still a role for sora ...... ib over other targeted agents.
@ast
Is there still a role for sora ...... ib over other targeted agents.
@en
type
label
Is there still a role for sora ...... ib over other targeted agents.
@ast
Is there still a role for sora ...... ib over other targeted agents.
@en
prefLabel
Is there still a role for sora ...... ib over other targeted agents.
@ast
Is there still a role for sora ...... ib over other targeted agents.
@en
P2093
P1476
Is there still a role for sora ...... nib over other targeted agents
@en
P2093
Daniela Cullurà
Elena Verri
Franco Nolé
Gaetano Aurilio
Maria Cossu Rocca
Roberto Iacovelli
P304
P356
10.1016/J.CRITREVONC.2016.01.014
P577
2016-01-19T00:00:00Z